Analysts Have Conflicting Sentiments on These Healthcare Companies: Dexcom (NASDAQ: DXCM) and Crispr Therapeutics AG (NASDAQ: CRSP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCMResearch Report) and Crispr Therapeutics AG (CRSPResearch Report).

Dexcom (DXCM)

BTIG analyst Marie Thibault maintained a Hold rating on Dexcom yesterday. The company’s shares closed last Thursday at $456.05, close to its 52-week high of $463.22.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 60.2% and a 63.2% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Boston Scientific.

Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $472.88.

See today’s analyst top recommended stocks >>

Crispr Therapeutics AG (CRSP)

In a report released yesterday, Raju Prasad from William Blair maintained a Buy rating on Crispr Therapeutics AG. The company’s shares closed last Thursday at $119.00.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 9.9% and a 48.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Allogene Therapeutics.

Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $177.40.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.